A DIGITAL HEALTH INFORMATION JOURNEY

“Empowering and equipping Europeans with health information
for active personal health management and adherence to treatment”
ABOUT US

The Gravitate Health is a public – private partnership with 41 members from Europe and the US, co-led by University of Oslo (coordinator) and Pfizer (industry lead), funded by the Innovative Medicines Initiative (IMI) – a joint undertaking of the European Commission, the European Federation of Pharmaceutical Industries and Associations (EFPIA), IMI2 Associated Partners.

Mission

The Gravitate Health mission is to equip and empower citizens with digital information tools that make them confident, active, and responsive in their patient journey, specifically encouraging safe use of medicines for better health outcomes and quality of life.

Vision

Engagement of citizens in their own health can only be achieved with access to actionable, understandable, relevant, reliable and evidence-based information that meets their specific needs, health context, and literacy level.

Ambition

To provide a key piece to advance this vision: the Gravitate Lens (G-lens®), which focuses (but does not conceal or filter) approved electronic product information (ePI) content, and offers a route for patients to access trustworthy, up-to-date information that better meet their individual needs.

0
.20
Project Launch
0
mo.
Duration
0
Mio Budget
0
Partners
ANNOUNCEMENT BOARD
PARTICIPATE
in our events, Connectathons, Hackathons, and more

FIND OUT
ENGAGE with us
ask questions, subscribe to ‘Under the Lens’ newsletter

FIND OUT
FOLLOW US

and share with us your feedback on Twitter

FIND OUT

OUR LATEST news
500x280px_GravitateHealth_Hackathon#1_article
500x280_Ecosystems_Events_Q4-2023-2
500x280px_GravitateHealth_First_ePI_EMA-n
Project Leads

Lorem Ipsum proin gravida nibh vel velit auctor aliquet. Aenean sollicitudin, lorem quis bibendum auctor, nisi elit consequatm proin gravida nibh vel ipsum, nec sagittis sem nibh id elit. Duis sed odio sit amet nibh vulputate cursus a sit amet mauris. Morbi accumsan ipsum velit. Nam nec tellus a odio tincidunt auctor a ornare odio. Sed non mauris vitae erat consequat.

Prof Anne Moen
Coordinator of Gravitate-Health and Professor in the Institute for health and society, University of Oslo
Gravitate-Health’s work with trusted, person-centered information—specifically ePI for medicines in use and language of choice—supports everyday health activities adding value to the pan-European deployment of ePrescription and cross-border dispensation. It is encouraging that Gravitate-Health enjoys broad support in EU and globally, leading to citizens’ capacity building for Digital Health and responsible healthcare transformation.
Dr Giovanna Ferrari
Senior Director, Pfizer and Gravitate-Health Project Lead

ePI is a hot topic globally and within Gravitate-Health we have been able to leverage our strong stakeholder partnerships to accelerate progress, building on developments in the EU to quickly define & publish a FHIR ePI standard that can be used globally – a real game changer!

João Almeida
HL7 Portugal; Gravitate-Health Product Owner

Following the establishment of our foundational elements, the project has now entered its growth phase. We have successfully developed the architecture for both FOSPS and G-Lens®, setting the stage for the creation of newer, more sophisticated lenses. Our goal is to leverage cutting-edge technological advancements to enhance health outcomes.

...Gravitate Health is an integrated digital health information project.

Gravitate Health services and the G-lens® will be developed and tested within the project, using an evaluation framework to test their ability to improve access to & understanding of health information, drive adherence and improve patient outcomes.

MILESTONES
G-lens® mock-ups and KPIs
100%
1st version of FOSPS architecture
100%
Concept validation of FOSPS platform and G-lens®
100%
Use case prioritizing for real world validation
95%
Gravitate Health FOSPS final version
71.5%
Gravitate Health Project Duration
67%
PARTNERS

41 partners from all over Europe and the US participate in the project.

Akershus Universitetssykehus
AstraZeneca AB
Bayer Aktiengesellschaft
Medicines Evaluation Board – MEB
Datapharm Limited
Datawizard SRL
Division of Clinical Informatics at Beth Israel Deaconess Medical Center
Eli Lilly and Company Limited
empirica Gesellschaft für Kommunikations-und Technologieforschung mbH
European Connected Health Alliance
F. Hoffmann – La Roche AG
Forum Europeen des Patients (EPF)
Grünenthal GmBH
Guardtime OÜ
HIMSS Europe GmBH
HL7 Europe
Karolinska Institutet
Københavns Universitet
MDSOL Europe Ltd (Medidata)
MINDVIEW Business Consulting & Research LTD
Norsk e-Helse AS
Norwegian Centre for eHealth Research
Novartis Pharma AG
PredictBy
Pfizer Limited (Project Lead)
Universitet i Oslo (Coordinator)
Serviços Partilhados do Ministério da Saúde, E.P.E.
Statens Legemiddelverk / (Norvegian Medicines Agency – NOMA)
The European Institute for Innovation through Health Data [i-HD]
The Synergist
Trifork Public A/S
Trinity College Dublin
UCB Biopharma SRl
Università Cattolica del Sacro Cuore – EMH
Viatris
Universidad Politécnica de Madrid (UPM) – LifeSTech
Servicio Madrileño de Salud
University College Dublin (UCD)
Oslo University Hospital
Janssen
Agencia Española de Medicamentos y Productos Sanitarios
SURVEYS

Participate in our surveys for consumers / patients / HCPs…

Subscribe to our newsletter
Citizens
Policy and regulatory institutions
Researchers
Industry, SMEs / developers
Healthcare providers / professionals

You are welcome to contact us for any matter,
just submit the following form.

    Supported by a grant from IMI
    This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 945334. The JU receives support from the European Union’s Horizon 2020 research and innovation programme, the European Federation of Pharmaceutical Industries and Associations [EFPIA], and Datapharm Limited. The total budget is 19.4M€ for a project duration of 60 months.

    Disclaimer:
    Information on this website reflects Project owner’s views and neither IMI nor the European Union, EFPIA, or or Datapharm Limited are liable for any use that may be made of the information contained herein.